Key facts
- It has raised $327.4M across 3 recorded rounds; the latest was Early Stage VC (Series B) ($224.0M) in Aug 2023.
- Notable investors include Alumni Ventures, Andreessen Horowitz, Mana Ventures, Fidelity Management & Research Company, Menlo Ventures — 22 tracked in total.
- Genesis Therapeutics has filed 3 Form Ds with the SEC since 2020, most recently Aug 2023 ($224.0M sold to 50 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 22 names
- ·Watchlist + deal alerts for Genesis Therapeutics
Funding rounds
3 roundsAbout Genesis Therapeutics
Developer of a computational platform designed for the discovery of small-molecule drugs. The company leverages a proprietary molecular artificial intelligence technology that drives the discovery and development of novel molecule drugs to treat patients suffering from severe and debilitating diseases, enabling the medical community to transform and optimize patient clinical outcomes.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Burlingame, CA, United States
- Founded
- 2019
- Employees
- 153
- Website
- genesis.ml/
- Ownership
- Privately Held (backing)
Genesis Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Genesis Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Genesis Therapeutics in its N-PORT filings yet. We sweep new filings monthly.